
Abcam plc
ABCZF
Updated: 24/09/2026, 05:36:28
No historical data available
Abcam plc is a prominent life sciences firm specializing in the creation, refinement, and provision of specialized agents and instruments crucial for scientific investigation, diagnostic procedures, and pharmaceutical development. Its diverse product portfolio primarily encompasses primary and secondary antibodies, along with conjugated antibodies and their respective conjugation kits. The company also offers singleplex and multiplex immunoassays, a variety of proteins and peptides (such as cytokines), and genetically modified cell lines and lysates. Additionally, their extensive catalog features other essential items like cellular activity kits, miRNA kits, various biochemical compounds, and tools designed for analyzing cell signaling pathways. Abcam caters to a wide clientele, including scientists and researchers at academic institutions and governmental research establishments, as well as professionals within the pharmaceutical, biotechnology, and diagnostics sectors. With a global footprint, the company maintains a presence across the Americas, Europe, the Middle East, Africa, China, Japan, and the broader Asia Pacific region. All its offerings are available for purchase directly via its online platform. Established in 1998, Abcam plc maintains its corporate headquarters in Cambridge, United Kingdom.
No summaries found.
- Share price
- $22.25
- Market cap
- $5.12B
- Exchange
- OTC
- Currency
- USD
- CEO
- Markus Lusser
- Employees
- 1,760
- IPO date
- 11/04/2011
- Beta
- 0.863
- Last dividend
- $0.00
- Day range
- $22.25 – $22.25
- 52-week range
- $22.25 – $22.25
- 1-day performance
- 0.68%
- 1-year performance
- 0.00%
- Current drawdown (1Y)
- 0.00%
- CIK
- 0001492074
- CUSIP
- N/A
- ISIN
- GB00B6774699
- Created
- 07/12/2025, 01:53:09
- Last update
- 24/09/2026, 05:36:28
Track Abcam plc with an AI analyst
See which prediction-market events move ABCZF, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.